Meeting
2015 ASCO Annual Meeting
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.
Authors
Richard S. Finn
University of California, Los Angeles Medical Center, Los Angeles, CA
Richard S. Finn , John Crown , Johannes Ettl , Tamas Pinter , Anu Thummala , Yaroslav V. Shparyk , Ravi Patel , Sophia Randolph , Sindy Kim , Xin Huang , Yuqiu Jiang , Cynthia Huang Bartlett , Dennis J. Slamon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00721409
Citation
J Clin Oncol 33, 2015 (suppl; abstr 575)
DOI
10.1200/jco.2015.33.15_suppl.575
Abstract #
575
Poster Bd #
63
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.
First Author: John Crown
Poster
2015 ASCO Annual Meeting
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).
First Author: Dennis J. Slamon
First Author: Richard S. Finn
Poster
2023 ASCO Annual Meeting
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.
First Author: Elisabeth Carola